-
公开(公告)号:US07342021B2
公开(公告)日:2008-03-11
申请号:US10067996
申请日:2002-02-08
申请人: Ruiping Liu , Hans-Jurgen Ernst Hess , Allen Hopper , Ashok Tehim , Yajing Rong
发明人: Ruiping Liu , Hans-Jurgen Ernst Hess , Allen Hopper , Ashok Tehim , Yajing Rong
IPC分类号: C07D473/34 , A61K31/52 , A61P37/08 , A61P25/28 , A61P29/00
CPC分类号: C07D473/40
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
-
公开(公告)号:US20080119495A1
公开(公告)日:2008-05-22
申请号:US11956871
申请日:2007-12-14
申请人: Ruiping LIU , Hans-Jurgen Ernst Hess , Allen Hopper , Ashok Tehim , Yajing Rong
发明人: Ruiping LIU , Hans-Jurgen Ernst Hess , Allen Hopper , Ashok Tehim , Yajing Rong
CPC分类号: C07D473/40
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
-
公开(公告)号:US20080139583A1
公开(公告)日:2008-06-12
申请号:US12026198
申请日:2008-02-05
IPC分类号: A61K31/52 , A61P25/28 , C07D473/32
CPC分类号: C07D473/34 , C07D473/14
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
摘要翻译: 通过式I的新化合物实现PDE4抑制:其中R 1和R 2如本文所定义。
-
公开(公告)号:US07332486B2
公开(公告)日:2008-02-19
申请号:US10636979
申请日:2003-08-08
IPC分类号: C07D473/40 , A61K31/52 , A61P25/24 , A61P25/18 , A61P25/28
CPC分类号: C07D473/34 , C07D473/14
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
-
公开(公告)号:US20070093510A1
公开(公告)日:2007-04-26
申请号:US10636979
申请日:2003-08-08
申请人: Ashok Tehim , Allen Hopper , Ruiping Liu , Hans-Jurgen Hess , Yajing Rong
发明人: Ashok Tehim , Allen Hopper , Ruiping Liu , Hans-Jurgen Hess , Yajing Rong
IPC分类号: A61K31/52 , C07D473/14
CPC分类号: C07D473/34 , C07D473/14
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
摘要翻译: 通过式I的新化合物实现PDE4抑制:其中R 1和R 2如本文所定义。
-
公开(公告)号:US20100004236A1
公开(公告)日:2010-01-07
申请号:US12393634
申请日:2009-02-26
IPC分类号: A61K31/52 , C07D473/34 , A61P25/28 , A61P25/18 , A61P25/36 , A61P25/24 , A61P11/00 , A61P37/08 , A61P29/00 , A61P25/16 , A61P9/00 , A61P31/18 , C07D413/14 , A61K31/5377 , A61K31/496
CPC分类号: C07D473/34 , C07D473/14
摘要: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
摘要翻译: 通过式I的新化合物实现PDE4抑制:其中R1和R2如本文所定义。
-
公开(公告)号:US20090264416A1
公开(公告)日:2009-10-22
申请号:US12194146
申请日:2008-08-19
申请人: Koc-Kan Ho , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer , Andrew John Cooke , Andrew Stanley Edwards , David Jonathan Bennett
发明人: Koc-Kan Ho , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer , Andrew John Cooke , Andrew Stanley Edwards , David Jonathan Bennett
IPC分类号: A61K31/551 , C07D241/04 , C07D413/12 , A61K31/496 , C07D413/14 , C07D401/12 , A61K31/5377 , A61K31/535 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/497 , C07D243/08
CPC分类号: C07D295/192 , C07D241/04 , C07D243/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: The present invention relates to N-benzyl,N′-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N′-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.
摘要翻译: 本发明涉及具有通式I的N-苄基,N'-芳基羰基哌嗪衍生物,其包含其的药物组合物,以及这些N-苄基,N'-芳基羰基哌嗪衍生物在制备用于治疗 或预防与胆固醇和胆汁酸运输和代谢相关的动脉粥样硬化和相关疾病。
-
公开(公告)号:US08314091B2
公开(公告)日:2012-11-20
申请号:US12194146
申请日:2008-08-19
申请人: Koc-Kan Ho , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer , Andrew John Cooke , Andrew Stanley Edwards , David Jonathan Bennett
发明人: Koc-Kan Ho , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer , Andrew John Cooke , Andrew Stanley Edwards , David Jonathan Bennett
IPC分类号: A01N43/62 , A01N43/58 , A01N43/60 , A61K31/55 , A61K31/535 , A61K31/50 , A61K31/495 , A61K31/497 , A61K31/4965 , C07D243/00 , C07D487/22 , C07D491/00 , C07D498/00 , C07D243/08 , C07D413/00 , C07D239/02 , C07D241/36 , C07D271/00 , C07D487/00 , C07D495/00 , C07D497/00 , C07D513/00 , C07D417/00 , C07D419/00 , C07D241/02 , C07D403/00 , C07D411/00 , C07D295/00
CPC分类号: C07D295/192 , C07D241/04 , C07D243/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: The present invention relates to N-benzyl,N′-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N′-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.
摘要翻译: 本发明涉及具有通式I的N-苄基,N'-芳基羰基哌嗪衍生物,其包含其的药物组合物,以及这些N-苄基,N'-芳基羰基哌嗪衍生物在制备用于治疗 或预防与胆固醇和胆汁酸运输和代谢相关的动脉粥样硬化和相关疾病。
-
公开(公告)号:US20120015958A1
公开(公告)日:2012-01-19
申请号:US13060730
申请日:2009-08-26
申请人: Andrew John Cooke , David Jonathan Bennett , Andrew Stanley Edwards , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Koc Kan Ho , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer
发明人: Andrew John Cooke , David Jonathan Bennett , Andrew Stanley Edwards , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Koc Kan Ho , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer
IPC分类号: A61K31/496 , C07D417/06 , C07D405/06 , C07D409/06 , C07D403/06 , A61P3/04 , A61P9/10 , A61P7/00 , A61P1/00 , A61P3/06 , A61P3/10 , C07D413/06 , C07D401/06
CPC分类号: C07D263/34 , C07D213/56 , C07D277/56 , C07D307/68 , C07D333/38
摘要: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be substituted by hydroxy, cyano or halogen; R2 represents 1 or 2 optional halogens; R3 is (C1-6)alkyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.
摘要翻译: 本发明涉及具有通式I的1-(4-脲基苯甲酰基)哌嗪衍生物(我们提请您注意,该电子版本没有提供式I,如在本文摘要中提供的)。其中R1是 (C 1-8)烷基,(C 3-8)环烷基或(C 3-8)环烷基(C 1-3)烷基,其各自可被羟基,氰基或卤素取代; R2表示1或2个任选的卤素; R3是(C 1-6)烷基,(C 3-6)环烷基或(C 3-6)环烷基(C 1-3)烷基,其各自可被一个或多个卤素取代; A表示包含1-3个选自N,O和S的杂原子的杂芳基环系统,当X是C时,该环系统是5-或6-元,当X是N时,该环系是5元; n为1或2; 或其药学上可接受的盐; 涉及包含其的药物组合物,以及这些1-(4-脲基苯甲酰基)哌嗪衍生物在制备用于治疗或预防动脉粥样硬化和与胆汁酸和胆汁酸运输和代谢相关的相关疾病的药物中的用途。
-
公开(公告)号:US08759352B2
公开(公告)日:2014-06-24
申请号:US13060730
申请日:2009-08-26
申请人: Andrew John Cooke , David Jonathan Bennett , Andrew Stanley Edwards , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Koc-Kan Ho , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer
发明人: Andrew John Cooke , David Jonathan Bennett , Andrew Stanley Edwards , Andrew Laird Roughton , Irina Neagu , Jui-Hsiang Chan , Koc-Kan Ho , Nasrin Ansari , Michelle Lee Morris , Yajing Rong , Michael Ohlmeyer
IPC分类号: A61K31/496 , C07D213/56 , C07D263/34 , C07D277/56 , C07D307/68
CPC分类号: C07D263/34 , C07D213/56 , C07D277/56 , C07D307/68 , C07D333/38
摘要: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be substituted by hydroxy, cyano or halogen; R2 represents 1 or 2 optional halogens; R3 is (C1-6)alkyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.
摘要翻译: 本发明涉及具有通式I的1-(4-脲基苯甲酰基)哌嗪衍生物(我们提请您注意,该电子版本没有提供式I,如在本文摘要中提供的)。其中R1是 (C 1-8)烷基,(C 3-8)环烷基或(C 3-8)环烷基(C 1-3)烷基,其各自可被羟基,氰基或卤素取代; R2表示1或2个任选的卤素; R3是(C 1-6)烷基,(C 3-6)环烷基或(C 3-6)环烷基(C 1-3)烷基,其各自可被一个或多个卤素取代; A表示包含1-3个选自N,O和S的杂原子的杂芳基环系统,当X是C时,该环系统是5-或6-元,当X是N时,该环系是5元; n为1或2; 或其药学上可接受的盐; 涉及包含其的药物组合物,以及这些1-(4-脲基苯甲酰基)哌嗪衍生物在制备用于治疗或预防动脉粥样硬化和与胆汁酸和胆汁酸运输和代谢相关的相关疾病的药物中的用途。
-
-
-
-
-
-
-
-
-